| Name | Title | Contact Details |
|---|
IVP, a public listed company, was founded in 1929. We started with vegetable oils and later diversified into an array of fields We were originally part of the TATA Group but later got acquired by the Allanas. Today we are an integral part of the Allana Group. We were the first company to manufacture Foundry Chemicals in India in technical collaboration with M/s Ashland Inc way back in 1965 Our manufacturing plants at Tarapur and Bangalore have a combined annual capacity of approximately 50,000 MT per annum catering to the foundry, composites, refractory & insulation industries in India and neighboring countries.
Maximus Partners is the leading professional services firm for growth-oriented organizations, with deep expertise in both CFO Advisory and Retained and Contingent Search services. We have worked alongside private equity investors and executive teams at PE-backed, privately-held and publicly-traded organizations to support hundreds of finance functions and evaluate and/or place thousands of professionals. This includes providing assessments of people, processes and technology, recommending and implementing solutions, and leading searches to hire key personnel to drive value creation.
Bringing over 75 years of combined industry experience, Incline P&C Group is the premier insurance program market services firm. Privately owned and operated with an exclusive focus on the program insurance market, the executive teams experience and expertise combined with effective underwriting discipline and risk management provides each client with various platforms and associated services to meet almost any need in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
AESSEAL designs and manufactures sealing solutions for a sustainable future. We work with global customers in every major industrial sector to improve the reliability, safety and environmental performance of industrial equipment. An industry pioneer, we were founded in 1979 and operate from 231 locations in 104 countries, with a total focus on achieving exceptional quality: in terms of products, technical innovation, customer service, after sales support and care for the environment.